MDC develops a novel robotic system designed to enhance cancer diagnosis and treatment procedures. This technology focuses on advancing minimally invasive surgical capabilities for oncological applications. The company is currently preparing its devices for demonstration and clinical use.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for cancer diagnosis and treatment, such as biopsies and ablations, can be invasive, leading to extended patient recovery times and potential complications. The precision of these procedures can also be limited, impacting the accuracy of diagnosis and the effectiveness of treatment.
Solution
MDC is developing a robotic system designed to enhance the precision and reduce the invasiveness of surgical procedures for cancer diagnosis and treatment. This system aims to improve the accuracy of biopsies and ablations, leading to more effective oncological interventions. By utilizing robotics, the technology intends to minimize patient recovery time and reduce the risk of complications associated with traditional surgical methods. The system is currently in development and is intended for minimally invasive surgical procedures.
Target Audience
The primary target audience includes oncologists and surgeons specializing in cancer diagnosis and treatment, as well as hospitals and medical centers that perform minimally invasive surgical procedures.
Features
- Robotic system for minimally invasive surgical procedures
- Targeted application for biopsy and ablation techniques
- Focus on improving cancer diagnosis
- Aims to enhance precision in surgical interventions
- Designed to reduce patient recovery time